AMRN

MKT CAP:$296M

Amarin Corporation plc

Market Cap

$296M

Healthcare·Biotechnology·🇮🇪 Ireland·NASDAQ

Healthcare·Biotechnology·🇮🇪·NASDAQ

Stock Price

$14.51+$0.79 (+5.76%)

Apr 21, 2026

Company Details

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. It...

CEO

Aaron D. Berg

IPO Date

Apr 1, 1993

Website

www.amarincorp.com

Key Metrics TTM

Revenue

$239M

-46.0% YoY

Net Income

-$38M

EPS (Diluted)

-$1.86

Free Cash Flow

-$11M

Revenue / Share

$11.53

Gross Margin

62.6%

Operating Margin

-19.6%

Net Margin

-16.0%

FCF Margin

-4.7%

P/S

1.2x

P/E

—

Earnings Reports

Q3 2025

May 6, 2026

PENDING

Q2 2025

Jul 30, 2025

$73M+7.7%EPS -$0.68

Q1 2025

May 7, 2025

$42M-25.7%EPS -$0.76

FY 2024

Mar 12, 2025

$229M-25.5%EPS -$4.00

Q2 2024

Jul 31, 2024

$68M-15.7%EPS $0.07

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 19	$112M	$87M	-$5M
Q4 19	$143M	$113M	$5M
Q1 20	$155M	$120M	-$24M
Q2 20	$135M	$107M	$4M
Q3 20	$156M	$123M	-$7M
Q4 20	$167M	$132M	$7M
Q1 21	$142M	$114M	-$1M
Q2 21	$154M	$122M	$9M
Q3 21	$142M	$112M	-$13M
Q4 21	$144M	$114M	$16M
Q2 23	$80M	$43M	-$24M
Q4 23	$75M	$45M	-$5M
Q1 24	$57M	$32M	-$14M
Q2 24	$68M	$42M	-$524.6K
Q1 25	$42M	$25M	-$17M
Q2 25	$73M	$50M	-$16M

Valuation

Quarter	P/S	P/E
Q3 19	15.0x	—
Q4 19	17.6x	—
Q1 20	9.6x	—
Q2 20	4.7x	—
Q3 20	2.6x	—
Q4 20	3.2x	—
Q1 21	4.0x	2609.6x
Q2 21	3.0x	425.2x
Q3 21	3.5x	—
Q4 21	2.4x	179.2x
Q2 23	0.9x	—
Q4 23	0.8x	—
Q1 24	1.0x	—
Q2 24	1.0x	—
Q1 25	0.8x	—
Q2 25	1.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 19	$22M	$20M
Q4 19	-$9M	-$9M
Q1 20	$4M	$4M
Q2 20	$2M	$2M
Q3 20	$11M	$11M
Q4 20	-$38M	-$38M
Q1 21	-$19M	-$19M
Q2 21	-$15M	-$15M
Q3 21	-$5M	-$5M
Q4 21	-$28M	-$28M
Q2 23	$7M	$0
Q4 23	-$651.6K	-$651.5K
Q1 24	-$13M	-$13M
Q2 24	-$3M	-$3M
Q1 25	-$12M	-$12M
Q2 25	$17M	$17M

Capital Expenditures

Quarter	CapEx
Q3 19	$1M
Q4 19	$364.0K
Q1 20	$251.2K
Q2 20	$277
Q3 20	$1.0K
Q4 20	$252.0K
Q1 21	$3
Q2 21	$2
Q3 21	$4
Q4 21	$4
Q2 23	$7M
Q4 23	$14
Q1 24	$4
Q2 24	$4
Q1 25	$0
Q2 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 19	+103.2%	+50.7%
Q4 19	+85.3%	+26.3%
Q1 20	+111.5%	+86.5%
Q2 20	+34.3%	+27.0%
Q3 20	+39.2%	+39.8%
Q4 20	+16.7%	+16.2%
Q1 21	-8.3%	-19.8%
Q2 21	+14.2%	+11.1%
Q3 21	-9.2%	-5.1%
Q4 21	-13.6%	-19.8%
Q2 23	-43.6%	-27.4%
Q4 23	-51.2%	-45.1%
Q1 24	-60.2%	-54.8%
Q2 24	-53.2%	-47.0%
Q1 25	-47.6%	-43.6%
Q2 25	-3.5%	+10.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 19	$8M	7.1%
Q4 19	$8M	5.7%
Q1 20	$0	0.0%
Q2 20	$0	0.0%
Q3 20	$12M	7.4%
Q4 20	$12M	6.9%
Q1 21	$0	0.0%
Q2 21	$0	0.0%
Q3 21	$0	0.0%
Q4 21	$0	0.0%
Q2 23	$0	0.0%
Q4 23	$0	0.0%
Q1 24	$0	0.0%
Q2 24	$0	0.0%
Q1 25	$4M	10.3%
Q2 25	$6M	8.3%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q3 19	$9M	$21M	$61M	—
Q4 19	$11M	$96M	—	—
Q1 20	$10M	$31M	$102M	—
Q2 20	$10M	$28M	$65M	—
Q3 20	$10M	$27M	$94M	—
Q4 20	$9M	$27M	$90M	—
Q1 21	$9M	$39M	$67M	—
Q2 21	$6M	$34M	$73M	—
Q3 21	$8M	$35M	$68M	—
Q4 21	$6M	$33M	$59M	—
Q2 23	$6M	$19M	$32M	—
Q4 23	$5M	—	—	$44M
Q1 24	$6M	$19M	$20M	—
Q2 24	$4M	—	—	$39M
Q1 25	$5M	$20M	$17M	—
Q2 25	$5M	$24M	$15M	—

Revenue Segments

Quarter	License	Product	Licensing And Royalty
Q3 19	$158.0K	$112M	—
Q4 19	$1M	$142M	—
Q1 20	—	$152M	$3M
Q2 20	—	$134M	$2M
Q3 20	—	$155M	$1M
Q4 20	—	$166M	$1M
Q1 21	—	$141M	$787.0K
Q2 21	—	$154M	$715.0K
Q3 21	—	$141M	$596.0K
Q4 21	—	$144M	$769.0K
Q2 23	—	$65M	$15M
Q4 23	—	$71M	$4M
Q1 24	—	$55M	$1M
Q2 24	—	$48M	$20M
Q1 25	—	$41M	$982.0K
Q2 25	—	$47M	$26M

Revenue by Geography

Quarter	Europe	United States
Q1 25	$5M	$36M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$219M	$143M	$363M
Q2 22	$228M	$85M	$313M
Q3 22	$240M	$63M	$304M
Q4 22	$218M	$92M	$309M
Q1 23	$191M	$113M	$304M
Q2 23	$233M	$80M	$313M
Q3 23	$271M	$50M	$321M
Q4 23	$199M	$121M	$321M
Q1 24	$214M	$94M	$309M
Q2 24	$216M	$91M	$307M
Q3 24	$157M	$149M	$306M
Q4 24	$121M	$173M	$294M
Q1 25	$120M	$162M	$282M
Q2 25	$148M	$151M	$299M
Q3 25	$123M	$164M	$287M
Q4 25	$135M	$168M	$303M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 19	18M	+6.1%	+18.7%
Q4 19	17M	-2.4%	+9.0%
Q1 20	18M	+5.4%	+9.9%
Q2 20	20M	+10.7%	+20.8%
Q3 20	19M	-2.5%	+11.0%
Q4 20	20M	+2.4%	+16.5%
Q1 21	20M	-1.1%	+9.3%
Q2 21	20M	+1.8%	+0.5%
Q3 21	20M	-1.3%	+1.8%
Q4 21	20M	+1.3%	+0.7%
Q2 23	20M	+1.5%	+3.3%
Q4 23	20M	+0.2%	+1.7%
Q1 24	21M	+0.4%	+3.4%
Q2 24	21M	+0.3%	+2.4%
Q1 25	21M	+0.3%	+1.2%
Q2 25	21M	+0.4%	+1.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 19	$212.1K	530
Q4 19	$148.5K	965
Q1 20	$160.6K	965
Q2 20	$140.2K	965
Q3 20	$162.2K	965
Q4 20	$167.3K	1K
Q1 21	$142.2K	1K
Q2 21	$154.5K	1K
Q3 21	$142.0K	1K
Q4 21	$258.0K	560
Q2 23	$219.6K	365
Q4 23	$274.0K	275
Q1 24	$205.5K	275
Q2 24	$245.7K	275
Q1 25	$152.8K	275
Q2 25	$264.5K	275

Revenue / Employee